Chitosan-Based Nanoparticles for Mucosal Delivery of RNAi Therapeutics

Martirosyan, Alina; Olesen, Morten T. Jarlstad; Howard, Kenneth A.

doi:10.1016/b978-0-12-800148-6.00011-0

Cited by 31 publications

(18 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33,34 Martirosyan et al utilized the mucoadhesive properties of chitosan for the delivery of siRNA across the mucosal surfaces following local administration. 35 Prego et al reported that chitosan NPs increased the intestinal absorption of salmon calcitonin, due to their mucoadhesive character and intimate interaction with the intestinal barrier. 36…”

Section: Mucosal Drug Deliverymentioning

confidence: 99%

Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting

Garg¹,

Chauhan²,

Nagaich³

et al. 2019

Adv Pharm Bull

358

184

View full text Add to dashboard Cite

Nanoparticles (NPs) have been found to be potential targeted and controlled release drug delivery systems. Various drugs can be loaded in the NPs to achieve targeted delivery. Chitosan NPs being biodegradable, biocompatible, less toxic and easy to prepare, are an effective and potential tool for drug delivery. Chitosan is natural biopolymer which can be easily functionalized to obtain the desired targeted results and is also approved by GRAS (Generally Recognized as Safe by the United States Food and Drug Administration [US FDA]). Various methods for preparation of chitosan NPs include, ionic cross-linking, covalent cross-linking, reverse micellar method, precipitation and emulsion-droplet coalescence method. Chitosan NPs are found to have plethora of applications in drug delivery diagnosis and other biological applications. The key applications include ocular drug delivery, per-oral delivery, pulmonary drug delivery, nasal drug delivery, mucosal drug delivery, gene delivery, buccal drug delivery, vaccine delivery, vaginal drug delivery and cancer therapy. The present review describes the formation of chitosan, synthesis of chitosan NPs and their various applications in drug delivery.

show abstract

Section: Mucosal Drug Deliverymentioning

confidence: 99%

Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting

Garg¹,

Chauhan²,

Nagaich³

et al. 2019

Adv Pharm Bull

358

184

View full text Add to dashboard Cite

show abstract

“…The reported Mg-based micromotors rely on the combination of a CLR-loaded poly(lactic-co-glycolic acid) (PLGA) layer and a chitosan polymer layer covering on a propellant Mg core to offer high drug-loading capacity, along with biodegradability. The positively charged chitosan outer coating enables adhesion of the motor onto the stomach wall 35 , facilitating efficient localized autonomous release of CLR from the PLGA polymer coating. In contrast to acid suppression by PPIs, Mg-based micromotors can temporally and physically alter the local acidic environment by quickly depleting protons while propelling within the stomach 24 .…”

Section: Introductionmentioning

confidence: 99%

Micromotor-enabled active drug delivery for in vivo treatment of stomach infection

et al. 2017

View full text Add to dashboard Cite

Advances in bioinspired design principles and nanomaterials have led to tremendous progress in autonomously moving synthetic nano/micromotors with diverse functionalities in different environments. However, a significant gap remains in moving nano/micromotors from test tubes to living organisms for treating diseases with high efficacy. Here we present the first, to our knowledge, in vivo therapeutic micromotors application for active drug delivery to treat gastric bacterial infection in a mouse model using clarithromycin as a model antibiotic and Helicobacter pylori infection as a model disease. The propulsion of drug-loaded magnesium micromotors in gastric media enables effective antibiotic delivery, leading to significant bacteria burden reduction in the mouse stomach compared with passive drug carriers, with no apparent toxicity. Moreover, while the drug-loaded micromotors reach similar therapeutic efficacy as the positive control of free drug plus proton pump inhibitor, the micromotors can function without proton pump inhibitors because of their built-in proton depletion function associated with their locomotion.

show abstract

“…Therefore, developing formulations that are suitable and can be applied to oral delivery of miRNAs is highly sought. Literature has identified that chitosan [80], mannose modified chitosan [81], bovine milk-derived exosomes [82], bovine lactoferrin [83], lipidic [84], and PLGA-based nanoformulations [85] are employed for effective oral delivery of miRNAs/therapeutics. Hence, developing oral nanoformulation(s) of miRNAs is achievable and is highly recommended for its successful implementation into the clinic.…”

Section: Expert Opinionmentioning

confidence: 99%

COVID-19: fighting the invisible enemy with microRNAs

Chauhan

Jaggi

Chauhan

et al. 2020

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: The novel coronavirus (CoV) disease 2019 (COVID-19) is a viral infection that causes severe acute respiratory syndrome (SARS). It is believed that early reports of COVID-19 cases were noticed in December 2019 and soon after it became a global public health emergency. It is advised that COVID-19 transmits through human to human contact and in most cases, it remains asymptomatic. Several approaches are being utilized to control the outbreak of this fatal viral disease. microRNAs (miRNAs) are known signature therapeutic tool for the viral diseases; they are small non-coding RNAs that target the mRNAs to inhibit their post-transcriptional expression, therefore, impeding their functions, can serve as watchdogs or micromanagers in the cells. Areas covered: This review work delineated COVID-19 and its association with SARS and Middle East respiratory syndrome (MERS), the possible role of miRNAs in the pathogenesis of COVID-19, and therapeutic potential of miRNAs and their effective delivery to treat COVID-19. Expert opinion: This review highlighted the importance of various miRNAs and their potential role in fighting with this pandemic as therapeutic molecules utilizing nanotechnology.

show abstract

Chitosan-Based Nanoparticles for Mucosal Delivery of RNAi Therapeutics

Cited by 31 publications

References 121 publications

Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting

Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting

Micromotor-enabled active drug delivery for in vivo treatment of stomach infection

COVID-19: fighting the invisible enemy with microRNAs

Contact Info

Product

Resources

About